



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE
(Case No. 99,297)

PATENT

In application of:)
)
Yatvin *et al.*)
)
Serial No. 09/993,976)
)
Filed: November 5, 2001)
)
For: Covalent Conjugates of Biologically-Active)
Compounds with Amino Acids and Amino)
Acid Derivatives for Targeting to Physiologically)
Protected Sites)

Before the Examiner:
S. Jiang

Group Art Unit: 1600/2900

RECEIVED
JAN 28 2003
TECH CENTER
#7
2-8-03

RESPONSE TO RESTRICTION REQUIREMENT
MAILED DECEMBER 17, 2002

Commissioner of Patents
Washington, D.C. 20231

Sir:

Responsive to the Restriction Requirement mailed December 17, 2002, Applicants elect to prosecute Claims 1-11 and 18-19 designated as Group I by the Examiner.

Applicants further elect the specific composition of melatonin conjugated to felbamate for the treatment of epilepsy.

If Examiner Jiang believes it to be helpful, he or she is invited to contact the undersigned attorney by telephone at (312) 913-0001.

Respectfully submitted,
McDonnell Boehnen Hulbert & Berghoff

By:

Kevin E. Noonan, Ph.D.
Reg. No. 35,303

Date: January 17, 2003



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE
(Case No. 99,297)

GP 1617
RECEIVED
JAN 28 2003
TECH CENTER 1600/2900
PATENT

In application of:

Yatvin *et al.*

Serial No. 09/993,976

Filed: November 5, 2001

For: Covalent Conjugates of Biologically-Active
Compounds with Amino Acids and Amino
Acid Derivatives for Targeting to Physiologically
Protected Sites

Before the Examiner
S. Jiang

Group Art Unit: 1617

TRANSMITTAL LETTER

Commissioner of Patents
Washington, D.C. 20231

Sir:

In regard to the above-identified application:

1. We are transmitting herewith the attached
 - a. Response to Restriction Requirement
2. With respect to additional fees:
 - a. No additional fee is required.
3. Please charge the full amount of the fee, or credit any overpayment to Deposit Account No. 13-2490.
4. CERTIFICATE UNDER 37 C.F.R. 1.10: The undersigned hereby certifies that this Transmittal Letter and this paper, as described in paragraph 1 herein above, are being sent by U.S. Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, Washington, D.C. 20231 on this 17th day of January, 2003.

By:

Kevin E. Noonan, Ph.D.
Reg No. 35,303